paclitaxel has been researched along with Hematologic Diseases in 137 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.73) | 18.7374 |
| 1990's | 28 (20.44) | 18.2507 |
| 2000's | 75 (54.74) | 29.6817 |
| 2010's | 30 (21.90) | 24.3611 |
| 2020's | 3 (2.19) | 2.80 |
| Authors | Studies |
|---|---|
| Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A | 1 |
| Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gillen, J; Gordon, SW; Gray, HJ; Guntupalli, SR; Hagemann, AR; Hays, J; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, R; Schilder, RJ; Walker, JL | 1 |
| Exner, F; Flentje, M; Höcht, S; Kleine, P; Mantel, F; Müller, E; Polat, B; Richter, A; Ströhle, S; Weick, S; Zimmermann, M | 1 |
| Boban, T; Boraska Jelavić, T; Brčić, L; Vrdoljak, E | 1 |
| Du, D; Fang, M; Song, T; Wu, S; Zhang, X | 1 |
| Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M | 1 |
| Alazraki, AL; Amankwah, EK; Cash, T; Clark, D; George, BA; Metts, JL; Olson, TA; Wasilewski-Masker, KJ | 1 |
| Chen, YH; Huang, ST; Li, WS; Lin, CT; Wang, YP; Wu, HC | 1 |
| Bian, NN; Min, GT; Wang, YH | 1 |
| Benedetti Panici, P; Boccia, SM; Di Donato, V; Di Mauro, F; Giancotti, A; Musacchio, L; Muzii, L; Palaia, I; Perniola, G; Tomao, F | 1 |
| Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kawaguchi, Y; Kida, M; Koizumi, W; Kurosu, T; Matsumoto, T; Miyata, E; Ohno, T; Okuwaki, K; Uehara, K; Watanabe, M; Yamauchi, H | 1 |
| Belau, A; Braicu, I; Ehmke, M; Koehler, G; Koensgen, D; Ledwon, P; Lichtenegger, W; Markmann, S; Mustea, A; Scharf, JP; Schneidewind, L; Sehouli, J; Sommer, H; Zygmunt, M | 1 |
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M | 1 |
| Ajgal, Z; Alexandre, J; Boudou-Rouquette, P; Cessot, A; Chapuis, N; Emile, G; Fontenay, M; Goldwasser, F; Huillard, O; Tigaud, JM | 1 |
| Fujiwara, Y; Giranda, V; Hashiba, H; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Qian, J; Shepherd, SP; Tamura, T; Xiong, H; Yagishita, S; Yamamoto, N | 1 |
| Boven, E; Frederiks, CN; Guchelaar, HJ; Lam, SW | 1 |
| Ahmed, I; Aisner, J; Benenati, B; Chen, T; Deek, MP; Jabbour, SK; Kim, S; Zou, W | 1 |
| Batista, N; Gonzalez-de-la-Fuente, GA; Gutierrez, F; Nazco, GJ; Oramas, J | 1 |
| Baron, MH; Bessette, P; Colombo, A; Creutzberg, CL; de Boer, SM; Fyles, A; Haie-Meder, C; Katsaros, D; Khaw, P; Kitchener, HC; Kruitwagen, RF; Ledermann, JA; Mileshkin, L; Nijman, HW; Nout, RA; Ottevanger, PB; Powell, ME; Putter, H; Smit, VT; Verhoeven-Adema, KW | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Kamimura, K; Matsumoto, Y; Moriyama, M; Saijo, Y; Zhou, Q | 1 |
| Arbea, L; Cano, D; Ceniceros, L; Chopitea, A; Diaz-Gonzalez, JA; Hernandez, JL; Iragorri, Y; Legaspi, J; Martin-Romano, P; Martínez-Regueira, F; Ponz-Sarvise, M; Rodríguez, J; Sola, JJ; Subtil, JC | 1 |
| Dhanikula, AB; Dhanikula, RS; Panchagnula, R | 1 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Bordin, V; Bozzoni, S; Caldiera, S; Codecà, C; Di Maria, G; Ferrari, D; Fiore, J; Floriani, I; Foa, P; Luciani, A; Zonato, S | 1 |
| Fracasso, PM; Garcia, AA; Knight, D; Mannel, RS; Muggia, F; Sill, MW; Swensen, R; Tiersten, AD; Warshal, DP | 1 |
| Adams, G; Green, JA; Walking, J; Wong, H; Zekri, J | 1 |
| Clawson, A; Iglesias, J; Krekow, L; O'Shaughnessy, J; Robert, N; Stokoe, C | 1 |
| Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G | 1 |
| Ando, M; Hasegawa, Y; Isa, S; Kawaguchi, T; Kubo, A; Nakagawa, K; Ou, SH; Shiraishi, J; Takada, M; Tsuji, T; Tsujino, K | 1 |
| Agelidou, M; Emmanouilidis, C; Georgoulias, V; Hatzidaki, D; Karachaliou, N; Kontopodis, E; Kotsakis, A; Mountzios, G; Popis, E; Vardakis, N | 1 |
| Bergman, JJ; Blom, RL; Busch, OR; Hulshof, MC; Klinkenbijl, JH; Reitsma, JB; Richel, DJ; van Berge Henegouwen, MI; van Heijl, M; Wilmink, JW | 1 |
| Chen, XC; Jiang, N; Zhao, Y | 1 |
| Chu, Z; Huang, M; Lu, G; Mao, Y; Yuan, B; Zhang, X; Zou, Y | 1 |
| Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; Van der Gaast, A; Verweij, J | 1 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| Friedrichs, K; Hölzel, F; Jänicke, F | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Fukuda, M; Kasai, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Deckert, M; Hans, V; Kristof, RA; Neuloh, G; Schlegel, U; Schramm, J; Simon, M; Urbach, H | 1 |
| Ackland, S; Hall, K; Levi, J; Lewis, C; Marx, G | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Pallis, A; Samonis, G; Souglakos, J | 1 |
| Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW | 1 |
| Andersson, H; Boman, K; Parö, G; Puistola, U; Ridderheim, M; Rosenberg, P; Sorbe, B | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| Besse, B; Spano, JP | 1 |
| Gutierrez, M; Lhomme, C; Pautier, P | 1 |
| Calvert, S; Greco, FA; Hainsworth, JD | 1 |
| Blohmer, JU; Breidenbach, M; Göhring, UJ; König, E; Kurbacher, CM; Mallmann, P; Rein, DT; Schmidt, T; Schöndorf, T | 1 |
| Bertucci, F; Chabannon, C; Conte, M; Genre, D; Gravis, G; Houvenaeghel, G; Maraninchi, D; Viens, P; Viret, F | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Anderson, SJ; Brown, A; Desai, AM; Kardinal, CG; Lembersky, BC; Mamounas, EP; Scholnik, AP; Smith, RE | 1 |
| Morère, JF | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Cho, MJ; Kim, JS; Kim, Ki; Kim, SY | 1 |
| Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T | 1 |
| Bonnet, R; Deppermann, KM; Gatzemeier, U; Hessler, S; Kaukel, E; Macha, HN; Reck, M; Ulm, K; von Pawel, J | 1 |
| Baran, I; Coskun, H; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Turan, OF; Zarifoglu, M | 1 |
| Adamo, V; Alafaci, E; Ferraro, G; Laudani, A; Pergolizzi, S; Scimone, A; Sergi, C; Settineri, N; Spano, F; Spitaleri, G | 1 |
| Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA | 1 |
| Bonneterre, J; Catimel, G; Tubiana-Hulin, M | 1 |
| Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F | 1 |
| Asmar, L; Dakhil, S; Friedland, DM; Gregurich, MA; Hollen, C | 1 |
| Ang, P; Fong, KW; Foo, KF; Lee, KM; Leong, SS; Ong, YK; Tan, EH; Wee, J | 1 |
| Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG | 1 |
| Chang, HK; Chen, MF; Chen, SC; Cheung, YC; Hsueh, S; Leung, WM; Lin, YC; Tsai, CS | 1 |
| Athanasiadis, A; Athanasiadou, DC; Papakostoulis, T; Roussos, G; Stathopoulos, GP | 1 |
| Kietpeerakool, C; Srisomboon, J; Suprasert, P | 1 |
| Frgala, T; Odrázka, K; Petera, J; Spacek, J | 1 |
| Abdel-Wahab, M; Abitbol, A; Hamilton, K; Lewin, A; Markoe, A; Troner, M | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Alderden-Los, C; Beijnen, JH; Rosing, H; Schellens, JH; Sharma, A; Veltkamp, SA | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Cohen, RB; Cosgriff, TM; Eisenberg, PD; Hainsworth, JD; Healey, D; Langer, CJ; Liau, K; Madajewicz, S; Pierce, K; Simon, GR; Xu, H | 1 |
| Vapattanawong, P | 1 |
| Beeram, M; Hamilton, M; Hammond, LA; Hidalgo, M; Kreisberg, JI; Mita, MM; Nadler, P; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Wolf, J; Wood, D | 1 |
| Armstrong, DK; Bookman, MA; Bristow, RE; McGuire, W; Schilder, JM | 1 |
| Furlow, B | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Han, ES; Monk, BJ | 1 |
| Chung, HC; Im, CK; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Yoo, NC | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J | 1 |
| Bayo, J; Bernabé, R; Jiménez, J; Lomas, M; Lopez-Ladrón, A; Moreno, A; Ruiz, M; Salvador, J; Valero, M; Vicente, D | 1 |
| Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W | 1 |
| Gelmon, KA | 1 |
| Gomella, L; Greenberg, R; Hudes, GR; Khater, C; McAleer, C; Nathan, FE; Stern, C | 1 |
| Bunn, PA; Kelly, KL | 1 |
| Ajani, JA; Ilson, DH; Kelsen, DP | 1 |
| Bentley, S; Bernard, S; Brecher, M; Graham, M; Johnston, C; Serody, J; Shea, T; Steagall, A; Vaisman, A; Wiley, J | 1 |
| Bailey, NP; Boddy, A; Calvert, AH; Chapman, F; Gumbrell, L; Hughes, A; Humphreys, A; Robson, L; Siddiqui, N; Thomas, H | 1 |
| Baselga, J; Crown, JP; Currie, V; Forsythe, P; Gilewski, TA; Hakes, TB; Hudis, CA; Reichman, BS; Seidman, AD; Yao, TJ | 1 |
| Barrett, S; Crown, J; Currie, V; Gilewski, T; Gollub, M; Hudis, C; Lepore, J; Seidman, AD; Tiersten, A; Yao, TJ | 1 |
| Groshen, S; Jeffers, S; Morris, M; Muderspach, L; Muggia, F; Roman, L; Russell, C; Uziely, B | 1 |
| Bell, DR; Bishop, JF; Friedlander, M; Goldstein, D; Levi, JA; Millward, MJ; Olver, IN; Rischin, D; Smith, JG; Toner, GC | 1 |
| Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J | 1 |
| Crump, M; Eisenhauer, E; Fisher, B; Latreille, J; Shepherd, FA; Stewart, D; Tomiak, E | 1 |
| Burris, HA | 1 |
| Alberts, DS; Brooks, DJ | 1 |
| Bauknecht, T; Bochtler, H; Diergarten, K; du Bois, A; Lück, HJ; Meerpohl, HG; Möbus, V | 1 |
| Kerkhofs, L; Kok, TC; Splinter, TA; van der Gaast, A; Vos, R | 1 |
| Baselga, J; Currie, V; Fennelly, D; Gilewski, T; Hellmann, S; Holmes, F; Hortobagyi, G; Hudis, C; Maickel, N; Moynahan, M; Norton, L; Raptis, G; Riccio, L; Seidman, A; Sklarin, N; Surbone, A; Uhlenhopp, M; Usakewicz, J; Yao, TJ | 1 |
| Bowling, K; Chen, TL; Donehower, RC; Duerr, M; Grochow, LB; Kennedy, MJ; Noe, D; Rowinsky, EK; Sartorius, S; Zahurak, ML | 1 |
| Agelidou, M; Androulakis, N; Apostolopoulou, F; Dimopoulos, AM; Georgoulias, V; Hatzidaki, D; Heras, P; Kakolyris, S; Kourousis, C; Mavromanolakis, E; Papadakis, E; Papadimitriou, C; Tzannes, S; Vlachonicolis, J; Vossos, A | 1 |
| Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Kemmerich, M; Laubenbacher, C; Quasthoff, S; Theiss, F; Thödtmann, F | 1 |
| Androulakis, N; Bahlitzanakis, N; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Kamilaki, M; Kotsakis, A; Koukouraki, S; Koukourakis, MI; Kourousis, C | 1 |
| Canfield, VA; Geyer, CE; Goodwin, DK; Green, SJ; Martino, S; Meyers, FJ; Moinpour, CM; O'Sullivan, J; Osborne, CK | 1 |
| Chan, AT; Chiu, SK; Johnson, PJ; Leung, TW; Mok, TS; Yeo, W; Yu, P | 1 |
| Anagnostopoulos, A; Diakomanolis, E; Dimopoulos, MA; Fountzilas, G; Giannakoulis, N; Gika, D; Moulopoulos, LA; Papadimitriou, CA; Sarris, K; Voulgaris, Z | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Biesma, B; Fokkema, E; Groen, HJ; Kwa, B; Postmus, PE; Smit, EF; van Putten, JW | 1 |
| Bagiella, E; Balog, J; Benson, M; Fine, R; Heitjan, D; Judge, T; Macarthur, RB; O'Connor, J; Olsson, CA; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Zuech, N | 1 |
| Bianco, AR; Carlomagno, C; Casella, G; De Placido, G; De Placido, S; Ferrari, E; Fiorentino, R; Iodice, F; Lauria, R; Maffeo, A; Morabito, A; Perrone, F; Pignata, S; Ricchi, P; Tramontana, S; Varriale, E | 1 |
| Agelaki, S; Androulakis, N; Dimou, T; Georgoulias, V; Giannakakis, T; Hatzidaki, D; Kakolyris, S; Mavroudis, D; Parashos, M; Sarra, E; Vlachonikolis, J; Ziras, N | 1 |
| Adenis, A; Armand, JP; Baille, P; Blanc, C; Bonneterre, J; Clouet, P; de Forni, M; Dembak, M; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Rougier, P | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Atkinson, R; Coleman, R; Crawford, M; Cruickshank, M; Eggleton, P; Fleming, D; Graham, J; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Vasey, PA | 1 |
| Aletti, G; Beatrice, S; Carnelli, M; Ferrari, A; Frigerio, L; Garavaglia, E; Mangili, G | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Mavroudis, D; Souglakos, J; Tsavaris, N; Tsiafaki, P | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D | 1 |
| Beijnen, JH; Duchin, K; Koopman, FJ; Lieverst, J; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; van Tellingen, O | 1 |
| Burstein, HJ; Winer, EP | 1 |
| De Giorgi, U; Marangolo, M; Papiani, G; Rosti, G | 1 |
| Buijs, D; Gelderblom, H; Nooter, K; Ouwens, L; Sparreboom, A; Stoter, G; van Zomeren, DM; Verweij, J | 1 |
| Abratt, RP; Chasen, MR; Cronje, N; Fourie, L; Hacking, D; McMichael, G; Rapoport, BL; Vorobiof, DA | 1 |
| Bol, CJ; Brouwer, E; de Vries, R; Eskens, FA; Nooter, K; Palmer, PA; Sparreboom, A; van der Gaast, A; van Zuylen, L; Verweij, J | 1 |
| Choi, YH; Hong, DS; In, KH; Jeong, TJ; Kim, HK; Kim, JS; Kim, YH; Lee, KS; Lee, SN; Lee, YY; Nam, E; Park, HS | 1 |
| Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C | 1 |
| Domon, H; Fujimoto, S; Fujimoto, T; Fujino, T; Hareyama, H; Ishizaki, Y; Kaneuchi, M; Kawaguchi, I; Minobe, S; Sakuragi, N; Sato, C; Yamaguchi, T; Yamamoto, R; Yoshiaki, K | 1 |
| Belleguic, C; Blanchon, F; Coste, E; Fournel, P; Le Caer, H; Léna, H; Pérol, M; Pham, E; Robinet, G; Schuller-Lebeau, MP; Thomas, P; Vergnenègre, A; Vernejoux, JM | 1 |
| Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schneeweiss, B; Schüll, B | 1 |
| Armstrong, DK; Donehower, RC; Ettinger, DS; Grumbine, FC; McGuire, WP; Rosenshein, NB; Rowinsky, EK | 1 |
15 review(s) available for paclitaxel and Hematologic Diseases
| Article | Year |
|---|---|
S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Hematologic Diseases; Humans; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2019 |
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Docetaxel; Gastrointestinal Diseases; Hematologic Diseases; Humans; Neurotoxicity Syndromes; Paclitaxel; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor, EphA5; Receptor, EphA6; Taxoids; Tubulin | 2015 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Hematologic Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemicitabine in the treatment of epithelial ovarian cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Hysterectomy; Life Tables; Lymphatic Irradiation; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Radiation Injuries; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Bevacizumab in the treatment of ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Hematologic Diseases; Humans; Intestinal Perforation; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salvage Therapy; Vascular Endothelial Growth Factor A | 2007 |
Optimal use of docetaxel (Taxotere): maximizing its potential.
Topics: Antineoplastic Agents, Phytogenic; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Docetaxel; Hematologic Diseases; Humans; Paclitaxel; Taxoids | 1996 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Europe; Forecasting; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Ifosfamide; Kidney Diseases; Male; Multicenter Studies as Topic; Neoplasms, Second Primary; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2002 |
91 trial(s) available for paclitaxel and Hematologic Diseases
| Article | Year |
|---|---|
A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome | 2019 |
Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy, Adjuvant; Endometrial Neoplasms; Endometrium; Feasibility Studies; Female; Follow-Up Studies; Germany; Hematologic Diseases; Humans; Incidence; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Survival Analysis | 2013 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult | 2015 |
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Eruptions; Drug Synergism; Female; Hematologic Diseases; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Radiography; Salvage Therapy; Tumor Burden | 2015 |
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemoradiotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Survival Rate | 2016 |
A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Treatment Outcome | 2009 |
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Polyethylene Glycols; Recombinant Proteins | 2010 |
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Time Factors; Treatment Outcome; United States | 2011 |
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2002 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cimetidine; Clemastine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Life Tables; Middle Aged; Muscular Diseases; Nervous System Diseases; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Premedication; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Survival Rate | 2002 |
Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2002 |
Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Mesna; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cause of Death; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2003 |
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytoprotection; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prospective Studies; Protective Agents | 2003 |
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Treatment Outcome | 2004 |
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left | 2004 |
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Chemotherapy, Adjuvant; Female; Hematologic Diseases; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Survival Analysis; Treatment Outcome; Ventricular Function, Left | 2004 |
A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carboplatin; Carcinoma; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hyperglycemia; Life Tables; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2004 |
Chemo-radiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Esophagitis; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2004 |
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome | 2005 |
Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Epirubicin; Feasibility Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome | 2005 |
Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outpatients; Paclitaxel; Survival Rate | 2005 |
External beam radiotherapy and high-dose brachytherapy combined with cisplatin and paclitaxel in patients with advanced cervical carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Drug Eruptions; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Radiotherapy, Adjuvant; Surveys and Questionnaires; Survival Rate | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Thiazoles; Treatment Outcome; Urea | 2007 |
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Topotecan | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis | 2008 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2008 |
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Female; Gastrointestinal Diseases; Genes, erbB-2; Half-Life; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Trastuzumab | 2008 |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Biweekly paclitaxel in the treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Premedication; Treatment Outcome | 1995 |
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Hematologic Diseases; Hormones; Humans; Male; Nausea; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 1995 |
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 1995 |
The activity of paclitaxel in gastrointestinal tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate | 1995 |
A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Creatinine; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Function Tests; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 1995 |
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 1995 |
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bayes Theorem; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Salvage Therapy | 1995 |
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications.
Topics: Adult; Aged; Bacterial Infections; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Premedication; Risk Factors; Survival Analysis | 1994 |
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Hypersensitivity; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Rate; Treatment Outcome | 1996 |
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Equipment Failure; Erythrocyte Transfusion; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Home Infusion Therapy; Humans; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1996 |
Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1996 |
A phase I study of etoposide phosphate plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel | 1996 |
Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1997 |
A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 1997 |
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1998 |
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome | 1998 |
Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 1998 |
Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Treatment Outcome | 1998 |
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Neuromuscular Diseases; Paclitaxel; Pain Measurement; Palliative Care; Survival Analysis; Treatment Failure | 1998 |
A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome | 1998 |
Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms | 1999 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Resistance; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 1999 |
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Leukocyte Count; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Recombinant Proteins; Treatment Outcome | 1999 |
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Docetaxel; Female; France; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Constipation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2001 |
Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Endometrial Neoplasms; Feasibility Studies; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy; Radiotherapy, Adjuvant; Risk Factors | 2001 |
Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2001 |
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Stomach Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 2001 |
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Biological Availability; Female; Gastrointestinal Diseases; Glycerol; Hematologic Diseases; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mesothelioma; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2002 |
Malignant pleural mesothelioma: a phase II trial with docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids | 2002 |
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Time Factors | 2002 |
A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2002 |
Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Reference Values; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2002 |
31 other study(ies) available for paclitaxel and Hematologic Diseases
| Article | Year |
|---|---|
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia | 2021 |
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase I as Topic; Female; Genes, BRCA1; Genes, BRCA2; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2021 |
Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cone-Beam Computed Tomography; Female; Follow-Up Studies; Four-Dimensional Computed Tomography; Hematologic Diseases; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radiation Injuries; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tumor Burden; Vinorelbine | 2021 |
Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2017 |
Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Neoplasm Staging; Paclitaxel; Patient Compliance; Propensity Score; Radiotherapy, Conformal; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae | 2018 |
Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
Topics: Adolescent; Albumins; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Male; Paclitaxel; Recurrence; Salvage Therapy; Sarcoma; Young Adult | 2018 |
Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Female; Glycerol; Hematologic Diseases; Humans; Liposomes; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neutropenia; Paclitaxel; Therapeutic Equivalency; Tissue Distribution | 2018 |
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cohort Studies; Cystadenocarcinoma, Serous; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Germ-Line Mutation; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2019 |
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Case-Control Studies; Doxorubicin; Female; Hand-Foot Syndrome; Hematologic Diseases; Humans; Leukocyte Count; Male; Middle Aged; Monocytes; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Retrospective Studies; Sarcoma; Stomatitis; Thymus Neoplasms; Young Adult | 2015 |
Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation Dosage; Radiation Tolerance; Regression Analysis; Thoracic Vertebrae; Thrombocytopenia | 2016 |
Hematological toxicity of carboplatin for gynecological cancer according to body mass index.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Overweight; Paclitaxel | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Myelosuppression by chemotherapy in obese patients with gynecological cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Ideal Body Weight; Japan; Middle Aged; Obesity; Paclitaxel; Retrospective Studies; Taxoids; Thinness; Young Adult | 2016 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2016 |
Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: dose proportionality and hematological toxicity studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Burden; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Gels; Hematologic Diseases; Injections, Intravenous; Injections, Subcutaneous; Leukocyte Count; Liposomes; Male; Neutrophils; Paclitaxel; Rats; Rats, Sprague-Dawley | 2008 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2010 |
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Ethnicity; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Review Literature as Topic | 2011 |
Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Hematologic Diseases; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Survival Rate | 2013 |
Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Creatinine; Female; Hematologic Diseases; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Risk Factors; Sex Factors | 2013 |
Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Camptothecin; Female; Hematologic Diseases; Humans; Irinotecan; Kidney; Liver; Male; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyenes; Rats; Rats, Sprague-Dawley; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Oligodendroglioma; Paclitaxel; Prospective Studies; Radiotherapy; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; World Health Organization | 2002 |
[New data presented at ASCO 2002 concerning non-small cell bronchial cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2004 |
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2005 |
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Capsules; Central Nervous System Diseases; Chemistry, Pharmaceutical; Cyclosporine; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Polymers | 2007 |
A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2006 |
Toxic effects differ in combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2007 |
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Biological Availability; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Quinolines; Taxoids | 2002 |
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cisplatin; Drug Evaluation; Epilepsy, Tonic-Clonic; Female; Hematologic Diseases; Humans; Joint Diseases; Muscular Diseases; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases | 1989 |